CN1214798C - 用于治疗单纯疱疹和带状疱疹的诺卡软膏 - Google Patents
用于治疗单纯疱疹和带状疱疹的诺卡软膏 Download PDFInfo
- Publication number
- CN1214798C CN1214798C CNB021324158A CN02132415A CN1214798C CN 1214798 C CN1214798 C CN 1214798C CN B021324158 A CNB021324158 A CN B021324158A CN 02132415 A CN02132415 A CN 02132415A CN 1214798 C CN1214798 C CN 1214798C
- Authority
- CN
- China
- Prior art keywords
- ointment
- nocar
- cell wall
- wall skeleton
- test
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000002674 ointment Substances 0.000 title claims abstract description 17
- 241000169439 Nocar Species 0.000 title claims abstract description 14
- 208000009889 Herpes Simplex Diseases 0.000 title claims abstract description 7
- 208000007514 Herpes zoster Diseases 0.000 title claims abstract description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 33
- 108010039939 Cell Wall Skeleton Proteins 0.000 claims abstract description 22
- 210000004520 cell wall skeleton Anatomy 0.000 claims abstract description 22
- 238000002360 preparation method Methods 0.000 claims abstract description 16
- 239000012153 distilled water Substances 0.000 claims abstract description 11
- 244000005700 microbiome Species 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 11
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000003871 white petrolatum Substances 0.000 claims abstract description 7
- 108090000790 Enzymes Proteins 0.000 claims abstract description 5
- 102000004190 Enzymes Human genes 0.000 claims abstract description 5
- 210000004027 cell Anatomy 0.000 claims abstract description 5
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims abstract description 5
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims abstract description 5
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims abstract description 5
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000004519 grease Substances 0.000 claims abstract description 5
- 229940057995 liquid paraffin Drugs 0.000 claims abstract description 5
- 239000004480 active ingredient Substances 0.000 claims abstract description 4
- 239000003883 ointment base Substances 0.000 claims abstract description 4
- 238000010298 pulverizing process Methods 0.000 claims abstract description 4
- 238000000746 purification Methods 0.000 claims abstract description 4
- 241000894006 Bacteria Species 0.000 claims description 9
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 2
- RLXHBWXJEVDGPE-UHFFFAOYSA-M [Na+].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCCCCCCCO Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCCCCCCCO RLXHBWXJEVDGPE-UHFFFAOYSA-M 0.000 claims 1
- 238000012360 testing method Methods 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 8
- 239000003814 drug Substances 0.000 abstract description 7
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 abstract description 6
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 abstract description 5
- 208000002193 Pain Diseases 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 239000000284 extract Substances 0.000 abstract description 4
- 238000000034 method Methods 0.000 abstract description 4
- 230000000638 stimulation Effects 0.000 abstract description 4
- 241000196324 Embryophyta Species 0.000 abstract description 2
- 241001465754 Metazoa Species 0.000 abstract description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 abstract description 2
- 238000011047 acute toxicity test Methods 0.000 abstract description 2
- -1 liquid paraffin Chemical compound 0.000 abstract description 2
- 230000035945 sensitivity Effects 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 241001446247 uncultured actinomycete Species 0.000 abstract 2
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 241000187654 Nocardia Species 0.000 abstract 1
- 208000030961 allergic reaction Diseases 0.000 abstract 1
- 229960005150 glycerol Drugs 0.000 abstract 1
- 230000003285 pharmacodynamic effect Effects 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 238000003756 stirring Methods 0.000 description 13
- 239000007788 liquid Substances 0.000 description 12
- 235000011187 glycerol Nutrition 0.000 description 11
- 239000000047 product Substances 0.000 description 10
- 239000001963 growth medium Substances 0.000 description 9
- 239000007853 buffer solution Substances 0.000 description 8
- 238000001556 precipitation Methods 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 7
- 229920001817 Agar Polymers 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000008272 agar Substances 0.000 description 6
- 238000003556 assay Methods 0.000 description 5
- 238000009833 condensation Methods 0.000 description 5
- 230000005494 condensation Effects 0.000 description 5
- 238000007689 inspection Methods 0.000 description 5
- 238000009413 insulation Methods 0.000 description 5
- 238000011068 loading method Methods 0.000 description 5
- 238000012856 packing Methods 0.000 description 5
- 230000000242 pagocytic effect Effects 0.000 description 5
- 238000004321 preservation Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 4
- 208000017520 skin disease Diseases 0.000 description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 3
- 206010048768 Dermatosis Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 239000004141 Sodium laurylsulphate Substances 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000005842 biochemical reaction Methods 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 230000036449 good health Effects 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000028016 temperature homeostasis Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 208000004404 Intractable Pain Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000187563 Rhodococcus ruber Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical class CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002912 waste gas Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
检验内容 | 检验标准 | 检验结果 |
物理性状 | 白色脂质状软膏 | 白色脂质状软膏 |
PH值 | 5.0-7.0 | 5.0-7.0 |
最低装量检查 | 平均装量不少于标示装量(10g/管),每个容器装量不少于标示装量的95%为合格 | 装量为9.90g/管 |
糖鉴别试验 | 溶液呈蓝绿色 | 溶液呈蓝绿色 |
微生物限度检查 | 按《中华人民共和国药典》附录XIJ检查,符合规定者判为合格 | 合格 |
小鼠异常毒性实验 | 在观察期内,小鼠应全部健在,无异常反应,到期每只小鼠体重增加,判为合格。 | 合格 |
豚鼠异常毒性实验 | 在观察期内,豚鼠应全部健在,无异常反应,到期每只豚鼠体重增加,判为合格。 | 合格 |
效力实验 | 吞噬百分率:≥40% | 吞噬百分率:43.6% |
吞噬指数:≥0.20 | 吞噬指数:0.63 | |
细胞壁骨架含量测定 | A≥0.3 | A=0.324 |
检验结论 | 合格 |
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB021324158A CN1214798C (zh) | 2002-06-21 | 2002-06-21 | 用于治疗单纯疱疹和带状疱疹的诺卡软膏 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB021324158A CN1214798C (zh) | 2002-06-21 | 2002-06-21 | 用于治疗单纯疱疹和带状疱疹的诺卡软膏 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1465356A CN1465356A (zh) | 2004-01-07 |
CN1214798C true CN1214798C (zh) | 2005-08-17 |
Family
ID=34145181
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB021324158A Expired - Lifetime CN1214798C (zh) | 2002-06-21 | 2002-06-21 | 用于治疗单纯疱疹和带状疱疹的诺卡软膏 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1214798C (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108295095A (zh) * | 2017-01-11 | 2018-07-20 | 福建省山河药业有限公司 | 红色诺卡氏菌细胞壁骨架在制备治疗痤疮的药物/护肤品中的用途及其药物/护肤品组合物 |
CN108938674A (zh) * | 2017-05-27 | 2018-12-07 | 福建省山河药业有限公司 | 红色诺卡氏菌细胞壁骨架在制备治疗皮肤病变药物中的用途 |
CN111727235B (zh) * | 2019-01-15 | 2024-03-15 | 辽宁天安生物制药股份有限公司 | 赤红球菌产品及其制药用途 |
-
2002
- 2002-06-21 CN CNB021324158A patent/CN1214798C/zh not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CN1465356A (zh) | 2004-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108553403B (zh) | 一种嗜热栖热菌和酵母菌组合发酵产物的用途 | |
Bzducha-Wróbel et al. | Chemical composition of the cell wall of probiotic and brewer’s yeast in response to cultivation medium with glycerol as a carbon source | |
US20090023681A1 (en) | Method of using beta-glucan from schizophyllum commune | |
CN111801105B (zh) | 赤红球菌产品在治疗复发性阿弗他溃疡中的用途 | |
CN108517345A (zh) | 一种嗜热栖热菌和酵母菌组合发酵的方法 | |
WO2020182180A1 (zh) | 赤红球菌产品在治疗外阴白色病变中的用途 | |
CN1214798C (zh) | 用于治疗单纯疱疹和带状疱疹的诺卡软膏 | |
CN114456943B (zh) | 一株桦褐孔菌及其提取物及其应用 | |
AU717731B2 (en) | Antigenic preparations | |
CN1067246C (zh) | N-乙酰-d-氨基葡萄糖在制备治疗皮肤癣菌的药物中的应用 | |
CN1291725C (zh) | 用于治疗宫颈糜烂的红色诺卡氏菌细胞壁骨架制剂及其制法 | |
CN115400142B (zh) | 一种β-1,3/α-1,3-葡聚糖在制备调节皮肤微生态产品中的应用 | |
WO2022199453A1 (zh) | 赤红球菌产品在治疗放射病中的用途 | |
US20040138174A1 (en) | Use of n-acetyl-d-glucosamine in the manufacture of pharmaceutical useful for treating cervical erosion | |
SU1327791A3 (ru) | Штамм GRIсноSроRоN каSнIWаYама-продуцент вещества,обладающего стимулирующим действием на репаративные процессы кожи, и способ получени вещества, обладающего стимулирующим действием на репаративные процессы кожи | |
WO2021217693A1 (zh) | 一种水解假丝酵母和日本清酒酵母共生发酵产物的用途 | |
CN111494302A (zh) | 益生元美白抗衰老发酵化妆品 | |
CN1944427B (zh) | 一种大分子化合物、其制备方法及应用 | |
CN114437949B (zh) | 一种来源于西藏的酿酒酵母及其发酵产物和应用 | |
US20060127518A1 (en) | Red nocardia cell wall skeleton preparation process and its therapeutic use on treating cervical erosion | |
CN114437951B (zh) | 一种来源于喜马拉雅地区土壤的酿酒酵母及其发酵产物和应用 | |
KR20180125354A (ko) | 천연 복합 버섯 성분이 함유된 아토피 개선 연고 및 로션 | |
CN114437952B (zh) | 一种来源于土壤的酿酒酵母及其发酵产物和应用 | |
CN114762699B (zh) | 一种狐粪青霉培养物外用制剂 | |
JP3335177B2 (ja) | Mk7634物質およびその製造法、ならびにmk7634物質を含有する駆虫剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: LIAONING NAKEJIA BIOLOGICAL PHARMACEUTICAL CO., LT Free format text: FORMER NAME: SHENYANG SHENGBAOKANG BIOPHARMACEUTICAL INDUSTRY CO. LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 110015, No. 7, Wen Dong Road, Dongling District, Liaoning, Shenyang Patentee after: LIAONING NAKEJIA BIOPHARMACEUTICAL Co.,Ltd. Address before: 110015, No. 7, Wen Dong Road, Dongling District, Liaoning, Shenyang Patentee before: Shenyang Sunbellcom Bio-Pharmaceutical Co.,Ltd. |
|
ASS | Succession or assignment of patent right |
Owner name: SHENYANG NUOKE BIOLOGICAL ENGINEERING CO., LTD. Free format text: FORMER OWNER: LIAONING NAKEJIA BIOLOGICAL PHARMACEUTICAL CO., LTD. Effective date: 20140312 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 110015 SHENYANG, LIAONING PROVINCE TO: 110004 SHENYANG, LIAONING PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20140312 Address after: 321 room 17-3, 110004 Wen'an Road, Heping District, Liaoning, Shenyang, China Patentee after: Shenyang Bio Technology Co.,Ltd. Address before: 110015, No. 7, Wen Dong Road, Dongling District, Liaoning, Shenyang Patentee before: LIAONING NAKEJIA BIOPHARMACEUTICAL Co.,Ltd. |
|
ASS | Succession or assignment of patent right |
Owner name: LIAONING NAKEJIA BIOLOGICAL PHARMACEUTICAL CO., LT Free format text: FORMER OWNER: SHENYANG NUOKE BIOLOGICAL ENGINEERING CO., LTD. Effective date: 20140825 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 110004 SHENYANG, LIAONING PROVINCE TO: 110015 SHENYANG, LIAONING PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20140825 Address after: 110015, No. 7, Wen Dong Road, Dongling District, Liaoning, Shenyang Patentee after: LIAONING NAKEJIA BIOPHARMACEUTICAL Co.,Ltd. Address before: 321 room 17-3, 110004 Wen'an Road, Heping District, Liaoning, Shenyang, China Patentee before: Shenyang Bio Technology Co.,Ltd. |
|
ASS | Succession or assignment of patent right |
Owner name: SHENYANG NAKEJIA BIO-TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: LIAONING NAKEJIA BIOLOGICAL PHARMACEUTICAL CO., LTD. Effective date: 20141230 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 110015 SHENYANG, LIAONING PROVINCE TO: 117004 BENXI, LIAONING PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20141230 Address after: 117004, No. 1, No. 1, 8-2, Ann street, Shiqiao village, Lake District, Benxi, Liaoning Patentee after: Shenyang treating biological technology Co.,Ltd. Address before: 110015, No. 7, Wen Dong Road, Dongling District, Liaoning, Shenyang Patentee before: LIAONING NAKEJIA BIOPHARMACEUTICAL Co.,Ltd. |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160801 Address after: 117000, No. 1, No. 1, 8-2, Chun An street, Shiqiao Town, Benxi, Liaoning Patentee after: LIAONING GREATEST BIO-PHARMACEUTICAL Co.,Ltd. Address before: 117004, No. 1, No. 1, 8-2, Ann street, Shiqiao village, Lake District, Benxi, Liaoning Patentee before: Shenyang treating biological technology Co.,Ltd. |
|
CX01 | Expiry of patent term |
Granted publication date: 20050817 |
|
CX01 | Expiry of patent term |